Chemical Structure (Vyvanse 01)
Vyvanse Tablet, Chewable
Product Images NDC 59417-120
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Vyvanse (NDC 59417-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Vyvanse 02)
Figure 2 (Vyvanse 03)
This text seems to be presenting numerical values related to the change in PK (Pharmacokinetics) and CI (Confidence Interval) for the drugs Guanfacine, Venlafaxine, and Omeprazole. It also shows a graph with a time scale on the x-axis and the change relative to the reference on the y-axis. However, more context is needed to fully understand the meaning of these results.*
Figure 3 (Vyvanse 04)
Figure 4 (Vyvanse 05)
Figure 5 (Vyvanse 06)
Figure 6 (Vyvanse 07)
This appears to be a chart displaying the effectiveness of Vyvanse compared to a placebo over a period of time post-dose (in hours). The chart shows that Vyvanse consistently outperforms the placebo in the given time frame. The numbers on the vertical axis appear to indicate the level of effectiveness, while the numbers on the horizontal axis indicate the time post-dose. The significance of the number "330" is not clear.*
Figure 7 (Vyvanse 08)
Figure 8 (Vyvanse 09)
Principal Display Panel (10 mg Capsule Bottle Label)
This is a medication guide for capsules containing isdexamfetamine dimesylate with the NDC number 59417-101-10. It is recommended to be stored at room temperature within the range of 20°C to 25°C (68°F to 77°F) and can be stored between 16°C to 30°C (59°F to 86°F). The medication should be dispensed in a tight container that is light-resistant according to the guidelines provided by USP. Takeda Pharmaceuticals America, Inc., located in Lexington, MA 02421, distributes the medication. Copyrighted in 2020, the medication is patented under US Pat. Nos. 7,105,488 and 7,228,726.*
Principal Display Panel (20 mg Capsule Bottle Label)
This is a medication guide for a product called "B" with a code number of 70041838. The guide instructs the pharmacist to dispense the medication to patients and store it at room temperature in a light-resistant container. The product is distributed by Takeda Pharmaceuticals America, Inc. in Lexington, MA. The guide also includes patent information.*
Principal Display Panel (30 mg Capsule Bottle Label)
This is a medication description for a dimesylate capsule with a concentration of 30mg. The packaging contains 100 capsules and must be stored at room temperature between 20°C to 25°C, with excursions permitted between 15°C to 30°C. It is distributed by Takeda Pharmaceuticals America, Inc. with copyright reserved, and US Pat. Nos. 7,105,488 and 7,2287%. A medication guide must be dispensed to patients, and the medicine must be stored in a tight, light-resistant container as defined in the USP.*
Principal Display Panel (40 mg Capsule Bottle Label)
Principal Display Panel (50 mg Capsule Bottle Label)
Vyvanse (dimesylate) is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) and moderate to severe binge eating disorder. It is in the form of capsules and contains 50mg of isderamfetamine. This medication guide must be provided to the patients. It is distributed by Takeda Pharmaceuticals America Inc. and should be stored at room temperature between 20°C to 25°C. The container used for dispensing should be tight and light-resistant. However, excursions are permitted between 15°C to 30°C.*
Principal Display Panel (60 mg Capsule Bottle Label)
This is a medication guide for a product that comes in 100 capsules. The recommended storage is at room temperature, between 20°C and 25°C, with permissible temperature excursions between 16°C and 30°C. It is distributed by Takeda Pharmaceuticals America, Inc. and all rights are reserved under US Pat. Nos. 7,105,488 and 72287%. No further information is available from the provided text.*
Principal Display Panel (70 mg Capsule Bottle Label)
This is a medication prescription for 70mg Isdexamfetamine Dimesylate capsules, to be dispensed by a pharmacist to patients. The medication guide should be included with the prescription. The container should be stored at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). The container should be tight and light resistant. The medication is distributed by Takeda Pharmaceuticals America, Inc.*
Principal Display Panel (10 mg Tablet Bottle Label)
Vyvanse® (isdexamfetamine dimesylate) chewable tablets are to be stored at room temperature (20°C to 25°C or 68°F to 77°F) and should be dispensed in a tight, light-resistant container, as allowed between 15°C and 30°C (59°F to 86°F). Each patient should receive a medication guide from the pharmacist. Takeda Pharmaceuticals America, Inc., located in Lexington, Massachusetts, distributed the medication.*
Principal Display Panel (20 mg Tablet Bottle Label)
This text is a medication guide for Vyvanse® (lisdexamfetamine dimesylate) chewable tablets. The guide provides instructions for proper storage between 20°C to 25°C (68°F to 77°F), with minor temperature deviations allowed between 15°C-30°C (59°F to 86°F), as well as information on the manufacturer, dosage information, and ingredients. A pharmacist should dispense the guide to each patient.*
Principal Display Panel (30 mg Tablet Bottle Label)
Principal Display Panel (40 mg Tablet Bottle Label)
This text is a medication guide for Vyvanse. It provides information on how to store the medication, in which container it should be dispensed, and how to take it, which is by chewing the tablets completely before swallowing. Additionally, it indicates the distributing company, Takeda Pharmaceuticals America, Inc, and includes the NDC number and a copyright notice.*
Principal Display Panel (50 mg Tablet Bottle Label)
Attention Pharmacist: Dispense the accompanying Medication Guide to each patient. Store Vyvanse (isdexamfetamine dimesylate) chewable tablets at room temperature (20°C to 25°C or 68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F to 86°F). Dispense in a tight, light-resistant container as defined in the USP. Vyvanse is distributed by Takeda Pharmaceuticals America, Inc. and each bottle contains a total of 100 chewable tablets. Chew the tablets completely before swallowing and do not swallow them whole. The tablets contain lisdexamfetamine sylate 50 mg (equivalent to 28.9 mg lisdexamfetamine). See the package insert for dosage information.*
Principal Display Panel (60 mg Tablet Bottle Label)
This is a medication guide for Vyvanse chewable tablets distributed by Takeda Pharmaceuticals. The guide contains storage instructions, dosage information, and warnings for the pharmacist. Patients are advised to chew the tablets thoroughly before swallowing and not to swallow whole. The medication contains Lisdexamfetamine, which is equivalent to 34.7 mg Lisdexamfetamine. The NDGC number is 59417-120-01, and the product comes with 100 chewable tablets.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
